ZS805

ZS805 is a recombinant adeno-associated virus (rAAV)-based gene therapy developed for the treatment of Fabry disease. It utilizes a gene expression cassette equipped with a proprietary liver-specific promoter and an optimized human GLA (α-galactosidase A) gene, enabling targeted and efficient expression of α-galactosidase A in hepatocytes. This approach aims to provide long-term or potentially life-long therapeutic benefit from a single administration, addressing the underlying enzyme deficiency in Fabry disease. The drug is classified as an innovative biologic (class 1) and represents one of the first rAAV-based gene therapies for this indication in China[1][2][5].